Genomics and Genetics of Drug Resistance and Regulation of Malaria Parasite Development

Xin-zhuan Su
DOI: https://doi.org/10.1007/978-1-60761-512-5_19
2010-01-01
Abstract:Malaria kills more than a million people each year, mostly in tropical and subtropical regions (Snow et al., 2005; Cox et al., 2007). It is caused by infection of one of the four Plasmodium parasites, including Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. The monkey malaria parasite Plasmodium knowlesi has also been reported to infect humans (Singh et al., 2004). P. falciparum is the most deadly parasite but P. vivax is the most widespread species. Although P. vivax is generally regarded as non-lethal, it can cause severe disease in patients (Mendis et al,2001; Genton et al., 2008). Malaria can be treated and cured using antimalarial drugs, but parasites resistant to many drugs currently in use have been reported, including delayed clearance of parasites after treatment of artemisinin combination therapy (ACT) (Wongsrichanalai and Meshnick, 2008). In addition, vaccines to prevent infections of malaria parasites are still not available, and insecticide-resistant mosquitoes are spreading (Hemingway et al., 2004).
What problem does this paper attempt to address?